Biochemical efficacy and tolerability of allopurinol 300 - 600 mg/day versus benzbromarone 100 - 200 mg/day in GOUT patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN49563848

Enrollment

Registered

2007-02-26

Start date

2006-09-01

Completion date

Unknown

Last updated

2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia, gout Musculoskeletal Diseases Arthropathies

Interventions

Arm A: 1dd 300 mg allopurinol, when serum urate exceeds 0.30 mmol/L after eight weeks, dosage is increased to 2dd 300 mg Arm B: 1dd 100 mg benzbroamrone, when serum urate exceeds 0.30

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis based on crystal evidence or otherwise meeting the American Rheumatology Association (ARA) criteria 2. Baseline serum urate measured 3. Baseline urinary urate excretion measured 4. Estimated creatinine clearance more than 50 mL/min

Exclusion criteria

Exclusion criteria: 1. Contra-indication for study medication: allopurinol or benzbromarone 2. Poor compliance on allopurinol defined as serum oxipurinol less than 5 mg/L

Design outcomes

Primary

Measure	Time frame
Success on study medication: tolerability and attainment of serum urate less than 0.30 mmol/L	—

Secondary

Measure	Time frame
1. Relative decrease of serum urate 2. Adverse drug reactions profile 3. Pharmacokinetic analysis of serum oxipurinol levels	—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 5, 2026